Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecallantide for Acute HAE in Children and Adolescents
NCT01832896Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Aug 2013
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ecallantide in hereditary angioedema (HAE), sponsored by NYU Langone Health. Primary endpoint: Time to symptomatic improvement from acute attacks of hereditary angioedema at 28 days. Planned start Aug 2013; status: withdrawn.
02
Drugs
ecallantide
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT01832896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01832896.